DE60220771D1 - Hemmer von cyclinabhängigen kinasen als mittel gegen krebs - Google Patents

Hemmer von cyclinabhängigen kinasen als mittel gegen krebs

Info

Publication number
DE60220771D1
DE60220771D1 DE60220771T DE60220771T DE60220771D1 DE 60220771 D1 DE60220771 D1 DE 60220771D1 DE 60220771 T DE60220771 T DE 60220771T DE 60220771 T DE60220771 T DE 60220771T DE 60220771 D1 DE60220771 D1 DE 60220771D1
Authority
DE
Germany
Prior art keywords
inhibitors
cycline
dependent kinases
against cancer
agents against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220771T
Other languages
English (en)
Other versions
DE60220771T2 (de
Inventor
Peter Martin Fischer
Shudong Wang
Gavin Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DE60220771D1 publication Critical patent/DE60220771D1/de
Publication of DE60220771T2 publication Critical patent/DE60220771T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60220771T 2001-03-29 2002-03-26 Hemmer von cyclinabhängigen kinasen als mittel gegen krebs Expired - Fee Related DE60220771T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0107901 2001-03-29
GBGB0107901.1A GB0107901D0 (en) 2001-03-29 2001-03-29 Anti-cancer compounds
PCT/GB2002/001445 WO2002079193A1 (en) 2001-03-29 2002-03-26 Inhibitors of cyclin dependent kinases as anti-cancer agent

Publications (2)

Publication Number Publication Date
DE60220771D1 true DE60220771D1 (de) 2007-08-02
DE60220771T2 DE60220771T2 (de) 2008-03-06

Family

ID=9911848

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220771T Expired - Fee Related DE60220771T2 (de) 2001-03-29 2002-03-26 Hemmer von cyclinabhängigen kinasen als mittel gegen krebs

Country Status (16)

Country Link
US (2) US7262202B2 (de)
EP (1) EP1373253B1 (de)
JP (1) JP4294960B2 (de)
CN (1) CN100519553C (de)
AT (1) ATE365163T1 (de)
AU (1) AU2002249389B2 (de)
BR (1) BR0208447A (de)
CA (1) CA2440228A1 (de)
CZ (1) CZ20032637A3 (de)
DE (1) DE60220771T2 (de)
ES (1) ES2287263T3 (de)
GB (2) GB0107901D0 (de)
IL (1) IL158116A0 (de)
MX (1) MXPA03008833A (de)
NZ (1) NZ528347A (de)
WO (1) WO2002079193A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1562911B1 (de) 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
CA2507406A1 (en) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2004083203A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
FR2881742B1 (fr) * 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
WO2009040399A1 (en) * 2007-09-28 2009-04-02 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CA2707989A1 (en) * 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
ES2631655T3 (es) * 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
CN112831542B (zh) * 2020-12-30 2022-10-14 厦门大学 一种基于MALDI-TOF-MS体外筛选CDKs家族蛋白激酶抑制剂的方法
AR125798A1 (es) 2021-05-07 2023-08-16 Kymera Therapeutics Inc Degradadores cdk2 y usos de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233461B2 (de) * 1986-01-13 2002-05-29 American Cyanamid Company 4,5,6-Substituierte 2-Pyrimidinamine
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof

Also Published As

Publication number Publication date
US7262202B2 (en) 2007-08-28
CZ20032637A3 (cs) 2004-02-18
WO2002079193A8 (en) 2005-03-17
EP1373253B1 (de) 2007-06-20
IL158116A0 (en) 2004-03-28
BR0208447A (pt) 2004-03-02
MXPA03008833A (es) 2004-10-15
US20070185134A1 (en) 2007-08-09
US20040132746A1 (en) 2004-07-08
ATE365163T1 (de) 2007-07-15
GB0107901D0 (en) 2001-05-23
AU2002249389B2 (en) 2008-03-13
CA2440228A1 (en) 2002-10-10
NZ528347A (en) 2005-07-29
GB0207229D0 (en) 2002-05-08
GB2375534B (en) 2003-09-24
JP2004538260A (ja) 2004-12-24
DE60220771T2 (de) 2008-03-06
WO2002079193A1 (en) 2002-10-10
GB2375534A (en) 2002-11-20
CN100519553C (zh) 2009-07-29
ES2287263T3 (es) 2007-12-16
EP1373253A1 (de) 2004-01-02
CN1503794A (zh) 2004-06-09
JP4294960B2 (ja) 2009-07-15

Similar Documents

Publication Publication Date Title
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
MXPA04002914A (es) N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE318812T1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DK1567522T3 (da) Pyrimidinforbindelser
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
MY140291A (en) Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs
ATE531263T1 (de) Hemmer der bruton-tyrosinkinase
NO20070580L (no) Behandling av cancer.
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
ATE447955T1 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
TW200740808A (en) Inhibiteurs de proteines kinases
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
BRPI0416777A (pt) composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase
PT1551850E (pt) 2 oxo-voruscharina e seus derivados

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee